Literature DB >> 23036576

Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

Laura Evangelista1, Andrea Guttilla, Fabio Zattoni, Pier Carlo Muzzio, Filiberto Zattoni.   

Abstract

CONTEXT: Determination of tumour involvement of regional lymph nodes in patients with prostate cancer (PCa) is of key importance for the proper planning of treatment.
OBJECTIVES: To provide a critical overview of published reports and to perform a meta-analysis about the diagnostic performance of 18F-choline and 11C-choline positron emission tomography (PET) or PET/computed tomography (CT) in the lymph node staging of PCa. EVIDENCE ACQUISITION: A Medline, Web of Knowledge, and Google Scholar search was carried out to select English-language articles published before January 2012 that discussed the diagnostic performance of choline PET to individualise lymph node disease at initial staging in PCa patients. Articles were included only if absolute numbers of true-positive, true-negative, false-positive, and false-negative test results were available or derivable from the text and focused on lymph node metastases. Reviews, clinical reports, and editorial articles were excluded. All complete studies were reviewed; thus qualitative and quantitative analyses were performed. EVIDENCE SYNTHESIS: From the year 2000 to January 2012, we found 18 complete articles that critically evaluated the role of choline PET and PCa at initial staging. The meta-analysis was carried out and consisted of 10 selected studies with a total of 441 patients. The meta-analysis provided the following results: pooled sensitivity 49.2% (95% confidence interval [CI], 39.9-58.4) and pooled specificity 95% (95% CI, 92-97.1). The area under the curve was 0.9446 (p<0.05). The heterogeneity ranged between 22.7% and 78.4%. The diagnostic odds ratio was 18.999 (95% CI, 7.109-50.773).
CONCLUSIONS: Choline PET and PET/CT provide low sensitivity in the detection of lymph node metastases prior to surgery in PCa patients. A high specificity has been reported from the overall studies. Studies carried out on a larger scale with a homogeneous patient population together with the evaluation of cost effectiveness are warranted.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036576     DOI: 10.1016/j.eururo.2012.09.039

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  77 in total

1.  Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database.

Authors:  D Gabriele; D Collura; M Oderda; I Stura; C Fiorito; F Porpiglia; C Terrone; M Zacchero; C Guiot; P Gabriele
Journal:  World J Urol       Date:  2015-08-15       Impact factor: 4.226

Review 2.  Advances in Imaging in Prostate and Bladder Cancer.

Authors:  Abhishek Srivastava; Laura M Douglass; Victoria Chernyak; Kara L Watts
Journal:  Curr Urol Rep       Date:  2017-09       Impact factor: 3.092

Review 3.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

4.  Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.

Authors:  Changhoon Song; Hyun-Cheol Kang; Jae-Sung Kim; Keun-Yong Eom; In Ah Kim; Jin-Beom Chung; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  Strahlenther Onkol       Date:  2015-07-10       Impact factor: 3.621

Review 5.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 6.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 7.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 8.  Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

Authors:  Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

Review 9.  [Focus on molecular imaging in prostate cancer].

Authors:  L Michaud; K A Touijer
Journal:  Prog Urol       Date:  2016-09-20       Impact factor: 0.915

10.  Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Katarzyna J Macura; Anthony Ciarallo; Esther Mena; Amanda Blackford; Rosa Nadal; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci; Ashley E Ross; Philip W Kantoff; Daniel P Holt; Robert F Dannals; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-10-22       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.